Peritoneal carcinomatosis of colorectal origin treated by cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy at the Bulovka University Hospital
Authors:
P. Bartoška 1; F. Antoš 1; R. Vobořil 1; P. Vítek 2; J. Marx 1; P. Holečková 3; M. Novotný 1; M. Kengbaeva 1
Authors place of work:
Chirurgická klinika 1. lékařské fakulty Univerzity Karlovy a Nemocnice Na Bulovce, Praha, subkatedra koloproktologie IPVZ Praha
1; Proton Therapy Center Czech, Praha
2; Ústav radiační onkologie, Nemocnice Na Bulovce a 1. lékařské fakulty Univerzity Karlovy, Praha
3
Published in the journal:
Rozhl. Chir., 2021, roč. 100, č. 10, s. 490-496.
Category:
Original articles
doi:
https://doi.org/10.33699/PIS.2021.100.10.490–496
Summary
Introduction: Peritoneal carcinomatosis (PK) of colorectal origin is a malignant tumour of the peritoneum caused by spreading of colorectal carcinoma (KRK) over the peritoneal surface of the abdominal cavity and its organs. PK occurs as a synchronous tumour in 15−20% of patients, and as metachronous disease in 25−50% of patients.
Methods: A group of 66 patients operated on for PK was retrospectively evaluated; 18 patients were excluded due to insufficient data. We evaluated 48 patients in total (22 men and 26 women) with mean age of 58 and 53 years, respectively; 12 patients (25%) were aged over 65 years. The patients were operated on between 2000 and 2019 using the Sugarbaker´s method of maximal cytoreduction (CRS) + HIPEC (Hyperthermic Intraoperative Peritoneal Chemotherapy). We evaluated the length, median survival, the incidence of complications and lethality in relation to the Peritoneal Carcinoma Index (PCI) and the Completeness of Cytoreduction (CC) score. The patients were divided into two subgroups according to the PCI score (0−12 and >12, respectively) and the CC score (CC 0−1 and CC 2−3, respectively).
Results: The mean survival was 26.3 months in the group with PCI up to 12 and 21.4 months in patients with PCI above 12 (p=0.02). In the group with CC 0−1 the mean survival was 27.1 months, while in the patients with the CC 2−3 it reached 12.6 months (p=0.06). The morbidity rate requiring an intervention was 18.7% and the lethality rate was 6.25% in the entire group. The median survival of the entire group was 22 months (13−34 months).
Conclusion: Literary references and our results are comparable, confirming the high efficiency of this method both in our country and worldwide. The use of CRS and HIPEC, associated with acceptable mortality and morbidity in selected patients with PK of colorectal origin, results in a significant extension of overall survival (OS).
Keywords:
peritoneal carcinomatosis − peritoneal carcinoma index − cytoreductive surgery − hyperthermic intraperitoneal chemotherapy − HIPEC
Zdroje
1. Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: population-based study. Int. J Cancer 2011 Jun1;128(11):2717−2725. doi: 10.1002/ijc.25596.
2. Van Gestel YRBM, de Hingh IHJT, van Herk-Sukel MPP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014 Aug 38(4):448−454. doi: 10.1016/j.canep.2014.04.004.
3. Verwall VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin. Oncol. 2003 Oct 15;21(20):3737−3743. doi:10.1200/ JCO.2003.04.187.
4. Bloemendal AL,van Ruth S, de Bree E, et al. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. Eur. J Surg. Oncol. 2005;31(10):1145−1151. doi: 10.1016/j. ejso.2005.06.002.
5. Franko J, Ibrahim Z, Gusani NJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 2010 Aug; 116(16):3756−3762. doi: 10.1002/cncr.25116.
6. Sadeghi B, Arvieux C, Glehen O, et al. Peritonal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000 Nov; 88:358−363. doi:10.1002/(SICI)1097- 0142(20000115).
7. Sugarbaker PH. Peritonectomy procedure. Ann Surg. 1995;221:29−42. doi: 10.1097/00000658-199501000-00004.
8. Yoon W, Alame A, Berrim R, et al. Peritoneal Surface Diesease Severity Score as a predictor od resectability in the treatment of peritoneal surface malignancies. Am Journal of Surg. 2014 March;207(3):403−407 doi: 10.1016/j.amjsurg. 2013.09.021.
9. Simkens GA, van Oudheusden T, Nierboer D, et al. Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC. Ann Surg Oncol. 2016;23:4214−4221 doi:10.1245/s10434-016-5211-6.
10. Endblad M, Ghanipour L, Cashin PH, et al. Prognostic scores for colorectal cancer with peritoneal metastases treated with cytoreductice surgery and chemotherapy. Int J Hyperthermia 2018 Dec;34(8):1390−1395 doi: 10.1080/02656736.2018.146466.
11. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. International Seminars in Surgical Oncology 2005 Feb;2(3):1−10 doi:10.1186/1477-7800-2- 3.
12. Dineen SP, Royal RE, Hughes MS, et al. A simplified preoperative assessment predicts complete cytoreduction and outcomes in patients with low-grade mutinous adenocarcinoma of the appendix. Annals of Surgical Oncology (2015);22:3640−3646. doi: 10.1245/ s10434-015-4446-y.
13. Flicek K, Ashfaq A, Johnson CD, et al. Correlation of radiologic with surgical peritoneal cancer index scores in patients with pseudomyxoma peritonei and peritoneal carcinomatosis: How well can we predict resectability? J Gastrointest Surg 2016; 20:307−312.doi: 10.1007/s11605-015- 2880-6.
14. Canbay E, Ishibashi H, Sako S, et al. Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World Journal of Surgery 2013;37:1271−1276. doi: 10.1007/s00268-013-1988-7.
15. Kusamura S, Baratti D, Hutanu I, et al. The role of baseline inflammatory- based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). EJSO 2015;41:1097−1105. doi: 10.1016/j. ejso.2015.04.005.
16. Carr NJ, Cecil TD, Mohamed F, et al. Consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: The results of the Peritoneal Surface Oncology Group International (PSOGI) modified delphi process. Am J Surg Pathol. 2016 Jan;40(1):14−26. doi:10.1097/ PAS.0000000000000535.
17. Kwakman R, Schrama AM, van Olmen, et al. Clinicopathological parameters in patients selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016 Jun;263(6):1102−111. doi:10.1097/ SLA0000000000001593.
18. Barrati D, Kusamura S, Iusco D, et al. Should a history of extraperitoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases? Dis. Colon Rectum 2018;61:1026−1034. doi: 10.1097/DCR.0000000000001156.
19. Yan Li, Yun-Feng Zhou, Han Liang, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World Journal of Gastroenterology 2016;22(30):6906−6916. doi: 10.3748/wjg. v 22. i30.6906.
20. Antoš F, Vítek P, Kopic J, et al. Cytoreduktivní chirurgie a hypertermická peroperativní chemoterapie (HIPEC) v léčbě malignit peritoneálních povrchů. Onkologická revue 2018;5(2):62−67, ISSN 2464-7195.
21. Klaver ChEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. The Lancet 2019 Jul;4(10):761−770 doi: 10.1016/S2468-1253(19)30239-0.
22. Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductice surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. The Lancet 2021 Feb;22(2):256−266 doi: 10.1016/S1470- 2045(20)30599-4.
23. Lin EK, Hsieh MCh, Chen ChH, et al. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis. Medicine 2016 Nov.;95:52(e5522). doi: 10.1097/ MD.0000000000005522.
24. Arslan NC, Bisgin T, Altay C, et al. Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer? JBUON 2018;23(suppl 1):77−83. ISSN:1107-0625.
25. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective Analysis of 523 patients from a multicentric French study. Journal of Clinical Oncology 2009 Nov;28(1):63−68 doi: 10.1200/ JCO.2009.23.9285.
26. Moran B, Cecil T, Chandrakumaran K, et al. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Disease 2015. doi: 10.1111/codi.12975.
27. Morano WF, Khalili M, Chi DS, et al. Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions – a systematic review. J Surg Oncol. 2018 Feb;117(2):245−259. doi:10.1002/ jso.24813.
28. Ludwigs K, Breimer ME, Brorson F, et al. Cytoreductive surgery and intraperitoneal chemotherapy (HIPEC or EPIC) in patients with colorectal adenocarcinoma and peritoneal carcinomatosis. Health Technology Assessment Database 2013;4. Record ID 32013000623.
29. Mehta SS, Gelli M, Agarwal D, et al. Complications of cytoreductive surgery and HIPEC in the treatment of peritoneal metastasis. Indian J Surg Oncol. 2016;7(2):225−229. doi: 10.1007/s13193- 016-0504-6.
30. Saxena A, Yan TD, Morris DL. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2010;17(5)1291−1301. doi: 10.1245/ s10434-009-0875-9.
31. Chia CS, Tan GHCh, Lim C, et al. Prospective quality of life for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23:2905−2913. doi: 10.1245/s10434-016-5203-6.
32. Cashin PH, Mahteme H, Syk I, et al. Quality of life and cost effectivness in a randomized trial of patients with colorectal cancer and peritoneal metastases. European Journal of Surgical Oncology 2018 Feb;44:983−990. doi: 10.1016/j. ejso.2018.02.012.
Štítky
Surgery Orthopaedics Trauma surgeryČlánok vyšiel v časopise
Perspectives in Surgery
2021 Číslo 10
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Sacral neuromodulation for faecal incontinence – 10 years experience and long-term outcomes of a specialized centre
- Bronchogenic cyst of gastric cardia – case report and literature review
- Delirious conditions in surgical ICU – case report
- Peritoneal surface malignancy spread − reoperations after cytoreductive surgery + HIPEC